5.08

1.50% 0.075

Imagenebio Inc (IMA)

Overview News Price History Discussions Forecast

Imagenebio Inc stock is traded at $5.08, with a volume of 8,047. It is up +1.50% in the last 24 hours and down -9.45% over the past month. ImageneBio Inc is a clinical-stage biopharmaceutical company developing therapeutics for patients with immunological, autoimmune and inflammatory diseases. The company's flagship asset, IMG-007, is a non-depleting anti-OX40 monoclonal antibody that binds specifically to OX40 receptor on activated T cells to block receptor binding to OX40 ligand (OX40L). IMG-007 is being developed to potentially treat multiple autoimmune and inflammatory diseases and disorders. The company operates in a single segment.

Previous Close:

$5.005

Open:

$5.08

24h Volume:

8,047

Relative Volume:

0.69

Market Cap:

$57.67M

Revenue:

$800.00K

Net Income/Loss:

$-45.07M

P/E Ratio:

-0.9661

EPS:

-5.2583

Net Cash Flow:

$-52.08M

1W Performance:

+4.74%

1M Performance:

-9.45%

6M Performance:

-15.47%

1Y Performance:

-44.78%

1-Day Range:

$4.925

$5.14

1-Week Range:

$4.865

$5.30

52-Week Range:

$3.94

$9.20

Imagenebio Inc Stock (IMA) Company Profile

Name

Imagenebio Inc

Sector

Healthcare (1069)

Industry

Biotechnology (595)

Phone

857-343-8292

Address

12526 HIGH BLUFF DRIVE, SAN DIEGO

Employee

Twitter

Next Earnings Date

2026-07-30

Latest SEC Filings

IMA's Discussions on Twitter

Compare IMA vs VRTX, REGN, ARGX, MRNA, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
IMA Imagenebio Inc	5.08	57.67M	800.00K	-45.07M	-52.08M	-5.2583
VRTX Vertex Pharmaceuticals Inc	515.44	130.42B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	781.49	81.67B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	984.39	61.56B	4.16B	1.29B	734.26M	19.58
MRNA Moderna Inc	143.97	54.54B	2.23B	-3.19B	-1.60B	-8.1462
RVMD Revolution Medicines Inc	203.77	43.59B	742.00K	-1.37B	-1.07B	-7.0731

Imagenebio Inc Stock (IMA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Nov-25-25	Resumed	Wedbush	Underperform
Oct-24-25	Initiated	Leerink Partners	Outperform

Imagenebio Inc Stock (IMA) Latest News

Sep 08, 2026

ImageneBio to Participate in H.C. Wainwright 28th Annual Global Investment Conference in New York - The Manila Times

Sep 08, 2026

A biotech CEO will speak in New York. ImageneBio will archive the webcast for 90 days. - Stock Titan

Sep 08, 2026

Sep 04, 2026

ImageneBio, Inc. (NASDAQ: IMA) Share Price, IMA Stock News, IMA Share Price & Updates - Kalkine

Sep 04, 2026

Aug 31, 2026

IMA Q2 2026 Earnings: Narrower EPS Loss Beats Estimates, Shares Slip 6.4%Earnings Call Highlights - vinanet.vn

Aug 31, 2026

Aug 29, 2026

ImageneBio (IMA) Edges Higher to $5.34 as Bulls Defend Key SupportPost-Earnings Moves - vinanet.vn

Aug 29, 2026

Aug 22, 2026

ImageneBio (IMA) Market: Finishes 1.78% Lower at $5.51 in the Current Update; Technical View: the Price Remains Bounded by the Supplied Support and Resistance on the DayCorrective Wave - vinanet.vn

Aug 22, 2026

Aug 21, 2026

ImageneBio, Inc. (NASDAQ:IMA) Receives Consensus Rating of "Hold" from Brokerages - MarketBeat

Aug 21, 2026

HC Wainwright Initiates ImageneBio at Buy With $28 Price Target - marketscreener.com

Aug 21, 2026

Blue Owl Capital Holdings LP Invests $5.41 Million in ImageneBio, Inc. $IMA - MarketBeat

Aug 21, 2026

Aug 19, 2026

ImageneBio (NASDAQ:IMA) Trading 1.8% HigherWhat's Next? - MarketBeat

Aug 19, 2026

Aug 18, 2026

ImageneBio Reports Inducement Grants under Nasdaq Listing Rule 5635(4) - marketscreener.com

Aug 18, 2026

ImageneBio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Aug 18, 2026

Aug 17, 2026

ImageneBio (IMA) shifts CFO equity mix toward RSUs in new grant - Stock Titan

Aug 17, 2026

ImageneBio's New Hires Get Stock Awards as CFO Gets a Separate Award - Stock Titan

Aug 17, 2026

Aug 14, 2026